postgenom
era
computeraid
drug
design
cadd
consider
extend
rang
applic
span
almost
stage
drug
discoveri
pipelin
target
identif
lead
discoveri
lead
optim
preclin
clinic
trial
two
new
technolog
cadd
associ
target
identif
new
chemic
entiti
discoveri
focu
review
drug
research
develop
r
comprehens
expens
timeconsum
full
risk
estim
drug
concept
market
would
take
year
cost
us
million
averag
sever
new
technolog
henc
develop
appli
drug
r
shorten
research
cycl
reduc
expens
computeraid
drug
design
cadd
one
evolutionari
technolog
emerg
quantit
structureact
relationship
qsar
analysi
earli
concept
cadd
evolv
quickli
especi
recent
decad
unpreced
develop
structur
biolog
comput
capabl
cadd
technolog
includ
molecular
model
simul
becom
promis
drug
discoveri
recent
cadd
even
use
design
highli
select
ligand
certain
target
share
similar
structur
mani
protein
difficult
done
method
one
exampl
ration
design
select
inhibitor
ribosom
protein
kinas
postgenom
era
owe
dramat
increas
small
molecul
biomacromolecul
inform
cadd
tool
appli
almost
everi
stage
drug
r
greatli
chang
strategi
pipelin
drug
discoveri
indic
fig
cadd
tradit
applic
lead
discoveri
optim
extend
toward
two
direct
upstream
target
identif
valid
downstream
preclin
studi
admet
predict
review
highlight
recent
advanc
cadd
technolog
emphas
put
comput
tool
target
identif
new
chemic
entiti
discoveri
target
identif
valid
first
key
stage
drug
discoveri
pipelin
fig
howev
identif
valid
druggabl
target
among
thousand
candid
macromolecul
still
challeng
task
numer
technolog
address
target
develop
recent
genom
proteom
approach
major
tool
target
identif
exampl
proteom
approach
identif
bind
protein
given
small
molecul
involv
comparison
protein
express
profil
given
cell
tissu
presenc
absenc
given
molecul
method
prove
success
target
discoveri
labori
timeconsum
therefor
complementari
experiment
method
seri
comput
silico
tool
also
develop
target
identif
catalog
sequencebas
approach
structurebas
approach
sequencebas
approach
contribut
process
target
identif
provid
function
inform
target
candid
posit
inform
biolog
network
diseas
caus
extern
pathogen
bacteria
virus
uniqu
target
might
found
pathogen
compar
function
genom
human
correspond
genom
pathogen
exampl
dutta
et
al
use
subtract
genom
method
analyz
complet
genom
helicobact
pylori
h
pylori
identifi
set
gene
like
essenti
pathogen
absent
human
theori
possibl
recogn
target
pathogen
way
wherea
endogen
diseas
target
could
discov
analyz
differ
genom
normal
abnorm
tissu
good
exampl
issu
sever
novel
steroid
target
identifi
combin
use
bioinformat
function
analysi
hormon
respons
element
structurebas
approach
shown
promis
recent
year
use
comput
method
find
put
bind
protein
given
compound
either
genom
protein
databas
subsequ
use
experiment
procedur
valid
comput
result
one
comput
approach
revers
dock
set
ligand
given
target
dock
compound
known
biolog
activ
bind
site
threedimension
structur
given
protein
databas
protein
hit
identifi
manner
serv
potenti
candid
experiment
valid
accordingli
approach
refer
revers
dock
invers
dock
gener
procedur
target
identif
use
revers
dock
integr
biolog
technolog
shown
fig
includ
four
step
revers
dock
small
molecul
select
hit
protein
hit
protein
postprocess
bioinformat
analysi
select
candid
experiment
valid
use
biochem
andor
cellular
assay
final
possibl
necessari
determin
xray
crystal
nmr
structur
small
moleculeprotein
complex
verifi
target
atom
level
approach
requir
suffici
number
known
protein
structur
cover
divers
rang
drug
target
fig
protein
structur
usual
select
protein
data
bank
pdb
construct
protein
structur
predict
method
use
subset
pdb
exampl
paul
et
al
success
recov
correspond
target
four
unrel
ligand
help
revers
dock
method
revers
dock
web
server
target
fish
dock
tarfisdock
also
develop
identifi
new
drug
target
server
potenti
drug
target
databas
pdtd
construct
target
protein
collect
pdtd
select
literatur
sever
onlin
figur
drug
discoveri
pipelin
vs
computeraid
drug
design
cadd
tool
cadd
tool
initi
develop
lead
optim
qsar
expand
lead
discoveri
virtual
screen
cadd
tool
quickli
extend
toward
upstream
downstream
direct
along
drug
discoveri
pipelin
upstream
direct
bioinformat
revers
dock
method
usual
use
target
identif
target
identifi
silico
method
also
develop
predict
structur
experiment
determin
comput
method
use
predict
target
druggabl
design
compound
experi
downstream
direct
silico
admet
predict
physiolog
base
pharmacokinet
simul
conduct
model
preclin
test
usual
integr
silico
lead
discoveri
stage
reduc
cost
databas
drugbank
structur
protein
pdb
recent
tarfisdock
prove
tool
great
potenti
valu
identifi
target
antih
pylori
natur
product
colon
human
stomach
bacterium
h
pylori
major
caus
factor
gastrointestin
ill
gastric
cancer
howev
discoveri
antih
pylori
agent
difficult
task
lack
matur
protein
target
therefor
identifi
new
molecular
target
develop
new
drug
h
pylori
obvious
necessari
inhous
potenti
drug
target
databas
search
use
revers
dock
tool
tarfisdock
take
activ
natur
product
fig
discov
antih
pylori
screen
probe
homolog
search
reveal
among
candid
discov
revers
dock
diaminopimel
decarboxylas
peptid
deformylas
pdf
homolog
protein
genom
h
pylori
enzymat
assay
demonstr
natur
product
one
deriv
potent
inhibitor
h
pylori
pdf
hppdf
ic
valu
mm
respect
fig
xray
crystal
structur
hppdf
complex
hppdf
natur
product
analog
also
determin
fig
demonstr
atom
level
hppdf
potenti
target
screen
new
antih
pylori
agent
advantag
revers
dock
obviou
addit
identifi
target
candid
activ
compound
also
possibl
identifi
potenti
target
respons
toxic
andor
side
effect
drug
suppos
target
databas
contain
possibl
target
howev
revers
dock
still
certain
limit
major
one
protein
entri
protein
structur
databas
like
pdb
enough
cover
protein
inform
diseaserel
genom
second
one
approach
consid
flexibl
protein
dock
simul
two
aspect
produc
neg
fals
anoth
limit
score
function
revers
dock
accur
enough
produc
posit
fals
one
tendenc
overcom
shortag
express
bind
affin
andor
inhibit
activ
activ
probe
target
hit
determin
way
target
candid
select
function
valid
f
crystal
structur
natur
producttarget
candid
hppdf
complex
mean
bind
natur
product
target
candid
verifi
atom
level
imag
protein
gener
use
pymol
program
http
pymolsourceforgenet
wwwdrugdiscoverytodaycom
develop
new
dock
program
includ
protein
flexibl
accur
score
function
anoth
tendenc
integr
sequencebas
structurebas
approach
drug
discoveri
develop
past
year
perform
approxim
target
period
organ
compound
includ
natur
product
synthes
isol
howev
use
organ
chemic
drug
discoveri
seem
favor
exist
target
screen
avail
compound
addit
complet
human
genom
suggest
druggabl
target
drug
intervent
control
human
diseas
therefor
believ
larg
number
new
drug
least
mani
lead
hit
hide
exist
chemic
mine
howev
dig
sourc
hard
task
collect
exist
compound
screen
randomli
extrem
unpract
intoler
expens
timeconsum
although
virtual
screen
show
dawn
satisfi
requir
inde
recent
promis
advanc
virtual
screen
demonstr
effici
approach
discov
lead
activ
compound
virtual
screen
enrich
hit
rate
defin
number
compound
bind
particular
concentr
divid
number
compound
experiment
test
random
screen
accordingli
virtual
screen
involv
pipelin
drug
discoveri
practic
tool
nevertheless
mention
hit
produc
virtual
screen
exist
compound
old
drug
virtual
screen
find
new
medic
usag
exist
compound
drug
big
pharma
medicin
chemist
seek
new
chemic
entiti
nce
strictli
protect
compound
patent
least
two
kind
cadd
method
nce
discoveri
de
novo
drug
design
combinatori
librari
design
de
novo
drug
design
start
databas
complet
molecul
aim
build
complet
molecul
molecular
brick
build
block
chemic
fill
bind
site
target
molecul
complet
chemic
entri
could
construct
link
build
block
togeth
grow
embryo
molecul
guidanc
evalu
bind
affin
build
block
could
either
atom
fragment
function
group
small
molecul
use
atom
build
block
thought
ineffici
therefor
seldom
use
nowaday
fragment
link
approach
bind
site
map
identifi
possibl
anchor
point
function
group
group
link
togeth
form
complet
molecul
sequentialgrow
approach
molecul
grow
bind
site
control
appropri
search
algorithm
evalu
grow
possibl
score
function
differ
dockingbas
virtual
screen
fragmentbas
de
novo
design
perform
sampl
whole
compound
space
obtain
novel
structur
limit
avail
databas
qualiti
grow
step
strongli
depend
previou
step
step
chemic
go
wrong
would
lead
unaccept
result
fragment
link
approach
choos
linker
connect
fragment
togeth
complet
structur
problem
remark
drawback
approach
might
synthet
access
design
structur
advent
combinatori
chemistri
one
excit
develop
medicin
chemistri
last
decad
coupl
autom
technolog
highthroughput
screen
ht
offer
great
potenti
discov
new
drug
lead
technolog
allow
thousand
even
million
compound
synthes
time
howev
mani
product
huge
librari
redund
also
make
sens
valid
assay
million
compound
addit
found
larg
number
compound
synthes
result
remark
increas
drug
candid
though
number
compound
synthes
screen
increas
sever
order
magnitud
initi
focu
combinatori
librari
design
select
divers
set
compound
assumpt
maxim
divers
would
result
broad
coverag
bioactiv
space
henc
would
maxim
chanc
find
drug
lead
creation
divers
compound
librari
central
claim
task
combinatori
chemistri
sinc
incept
suggest
assumpt
assess
divers
studi
last
decad
synthes
chemic
librari
reason
size
consider
hit
rate
structur
inform
properti
studi
target
taken
consider
filter
redund
compound
thu
critic
challeng
firstli
select
set
fragment
best
potenti
part
new
drug
lead
given
target
secondli
set
proper
criteria
product
judgment
screen
overcom
first
challeng
three
type
virtual
librari
suggest
focus
librari
target
librari
primari
screen
librari
focus
librari
built
basi
lead
molecul
pharmacophor
gear
toward
one
particular
molecular
target
target
librari
design
find
drug
lead
specif
target
primari
screen
librari
larg
combinatori
librari
use
randomli
find
new
hit
design
novel
scaffold
solv
second
problem
druglik
admet
structur
divers
introduc
librari
design
reduc
size
increas
effici
adopt
advantag
focus
librari
target
librari
well
integr
technolog
dockingbas
virtual
screen
druglik
admet
analysi
targetfocus
librari
design
method
develop
base
softwar
packag
call
also
develop
flowchart
shown
fig
start
structur
hit
therapeut
target
overal
skeleton
potenti
ligand
schemat
split
sever
fragment
accord
interact
mechan
physicochem
properti
bind
site
individu
fragment
librari
construct
fragment
take
account
bind
featur
fragment
bind
site
final
targetfocus
librari
studi
target
construct
judgment
structur
divers
druglik
admet
profil
bind
affin
targetfocus
librari
design
librarybas
genet
algorithm
appli
optim
focus
librari
newli
develop
druglik
filter
use
predict
druglik
profil
librari
molecular
dock
approach
employ
predict
bind
affin
librari
molecul
target
qualiti
fragment
librari
critic
final
focus
librari
least
three
way
construct
fragment
librari
extract
fragment
known
drug
ligand
inhibitor
activ
studi
target
effect
approach
collect
build
block
homolog
protein
usual
share
similar
structur
featur
characterist
especi
bind
site
activ
site
therefor
ligand
differ
target
belong
famili
share
common
fragment
thu
fragment
construct
targetfocus
librari
could
design
refer
structur
ligand
homolog
protein
target
also
fragment
could
isol
activ
hit
produc
primari
screen
ht
virtual
screen
effici
strategi
targetfocus
librari
design
screen
demonstr
recent
exampl
discov
human
cyclophilin
cypa
inhibitor
employ
dockingbas
virtual
screen
conjunct
chemic
synthesi
bioassay
binder
cypa
discov
four
show
high
cypa
ppias
inhibit
activ
ic
valu
mm
discov
new
chemic
entiti
cypa
inhibitor
potent
activ
targetfocus
librari
design
base
structur
hit
bind
mode
cypa
use
program
bind
mode
indic
small
molecular
cypa
binder
divid
three
part
part
interact
small
pocket
cypa
pocket
part
b
locat
larg
pocket
pocket
b
part
l
linker
b
interact
saddl
pocket
site
b
fig
select
fragment
part
fragment
fragment
targetfocus
librari
design
select
accord
interact
mode
primarili
screen
hit
binder
target
accordingli
fragment
leadlik
build
block
construct
librari
fragment
connect
whole
molecul
optim
interact
pose
bind
affin
use
dock
imag
gener
use
pymol
program
remark
bind
affin
inhibitori
activ
potent
compound
increas
time
activ
compound
discov
first
cycl
discoveri
technolog
progress
cadd
brought
paradigm
chang
pharma
research
institut
possibl
obtain
appropri
hit
within
sever
week
contribut
cadd
tradit
structurebas
pharmacophor
techniqu
qsar
major
tool
cadd
parallel
develop
combinatori
chemistri
ht
sinc
decad
ago
sever
new
technolog
librari
design
virtual
screen
druglik
analysi
admet
predict
becom
import
tool
computeraid
discoveri
new
drug
come
futur
addit
improv
individu
exist
cadd
techniqu
increas
accuraci
effect
virtual
screen
one
major
tendenc
cadd
technolog
develop
integr
comput
chemistri
biolog
togeth
chemoinformat
bioinformat
lead
new
topic
known
pharmacoinformat
impact
pharmaceut
develop
process
increas
success
rate
develop
candid
anoth
tendenc
cadd
technolog
enter
function
genom
studi
target
identif
particular
complet
human
genom
numer
pathogen
genom
effort
underway
understand
role
gene
product
biolog
pathway
human
diseas
exploit
function
sake
discov
new
drug
target
small
cellperm
chemic
ligand
use
increasingli
genom
approach
understand
global
function
genom
proteom
approach
refer
chemic
biolog
chemogenom
revers
dock
refer
comput
chemic
biolog
proven
effect
way
find
clue
new
target
contrari
cadd
techniqu
like
virtual
screen
librari
design
also
use
design
small
molecul
probe
illumin
molecular
mechan
underli
biolog
process
alter
perturb
function
target
protein
inhibit
activ
normal
function
postgenom
era
concept
computeraid
drug
design
cadd
extend
lead
discoveri
target
identif
lead
optim
preclin
clinic
trial
two
approach
silico
target
identif
sequencebas
structurebas
sequencebas
approach
bioinformat
method
appli
analyz
compar
multipl
sequenc
identifi
potenti
target
scratch
wherea
structurebas
approach
reversedock
method
might
help
identifi
target
candid
activ
compound
least
two
silico
strategi
discoveri
nce
de
novo
drug
design
combinatori
librari
design
especi
targetfocus
librari
design
demonstr
recent
exampl
discov
human
cyclophilin
inhibitor
druglik
admet
properti
consid
librari
design
